Gate Neurosciences

Neuroscience
#Autism #Gate Neurosciences #Neurodevelopmental disorders #Neuroscience #Preclinical investigations

Preclinical studies demonstrate potential of zelquistinel in autism

Robust efficacy in several preclinical models supports high translational potential of zelquistinel in autism and reflects broader opportunity across synaptic dysfunction disorders. Gate Neurosciences has announced the publication of new peer-reviewed research demonstrating the therapeutic potential of zelquistinel (GATE-251) to address symptoms of autism spectrum disorder… Read More

#News

Neuron
#Antidepressants #Biomarkers #Depression #Gate Neurosciences #Neuroscience #Phase I trial

Phase I clinical trial validates qEEG biomarker in CNS disorders

Gate Neurosciences has announced positive topline quantitative EEG (qEEG) biomarker and safety results from its Phase I multiple ascending dose study of apimostinel in healthy volunteers. The results demonstrated a dose-dependent increase in qEEG pharmacodynamic biomarkers of NMDA receptor target activation from baseline, compared with subjects… Read More

#News

Laboratory equipment
#Expansion #Gate Neurosciences #Lab space #Major depressive disorder #Neuroscience

Gate Neurosciences expands research operations

Gate Neurosciences has increased its R&D capabilities with new expanded research operations and lab facilities in Evanston, Illinois. The company hopes to further build the translational biomarker data package supporting its NMDA receptor modulator portfolio and advance foundational mechanism insights behind its synaptic function-enhancing molecules. Read More

#News